Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amir Haghighat

Interventional Cardiology Panama City, FL Medical Doctor

NPI 1235197518 CMS profile 237684

625 W Baldwin Rd Ste C, Panama City, FL 32405

Open in the dashboard

General payments

$34,571

485 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$14,312 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Amir Haghighat of Panama City, FL is reported in the CMS Open Payments database as having received $34,571 across 485 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $14,312 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 82nd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,024 48
2024 General $3,489 74
2023 General $2,169 58
2022 General $3,896 82
2021 General $4,154 41
2020 General $12,846 74
2019 General $5,993 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amir Haghighat
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Amir Haghighat were reported at $2,024. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Amir Haghighat Interventional Cardiology median Middle half National median
2019 $5,993 $1,097 $329–$3,048 $163
2020 $12,846 $473 $161–$1,480 $114
2021 $4,154 $677 $233–$1,827 $132
2022 $3,896 $978 $333–$2,724 $149
2023 $2,169 $1,136 $382–$2,986 $160
2024 $3,489 $1,181 $395–$3,326 $164
2025 $2,024 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $14,902 67 payments
  2. Abbott Laboratories $3,165 25 payments
  3. Medtronic Vascular, Inc. $2,545 33 payments
  4. Boston Scientific Corporation $2,009 25 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,091 19 payments
  6. Merck Sharp & Dohme Corporation $938 45 payments
  7. Cardiovascular Systems Inc. $934 13 payments
  8. Medtronic, Inc. $880 13 payments
  9. Amgen Inc. $813 32 payments
  10. Siemens Medical Solutions USA, Inc. $761 7 payments
  11. Other $6,532 206 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,019 448 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,400 12 payments
  3. Travel and Lodging $4,950 17 payments
  4. Education $127 7 payments
  5. Gift $75 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $14,513 45 payments
  2. SUPERA $2,609 17 payments
  3. Resolute $1,957 17 payments
  4. VERQUVO $1,252 55 payments
  5. WATCHMAN $1,246 7 payments
  6. LifeVest $1,091 19 payments
  7. Peripheral Orbital Atherectomy System $909 11 payments
  8. Repatha $797 31 payments
  9. Artis zee $761 7 payments
  10. Impella $556 6 payments
  11. Other $10,034 333 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

5,935

Median for Interventional Cardiology: 2,236

Drug cost

$1,214,019

Median for Interventional Cardiology: $380,412

Branded share of claims

37.7%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 410 $438,953
Entresto Sacubitril/Valsartan Brand 191 $268,376
Xarelto Rivaroxaban Brand 104 $134,376
Farxiga Dapagliflozin Propanediol Brand 112 $132,961
Repatha Sureclick Evolocumab Brand 103 $81,952
Brilinta Ticagrelor Brand 50 $41,055
Jardiance Empagliflozin Brand 29 $38,900
Ranolazine Er Ranolazine Brand 216 $19,879
Metoprolol Succinate Generic 481 $7,804
Clopidogrel Clopidogrel Bisulfate Brand 678 $7,522

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 109 billing codes

Paid by Medicare

$705,275

Of which drugs: $2,095

Medicare patients

2,232

Average age 76

Services billed

6,573

1,120 women, 1,112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 66%
Arthritis 59%
Diabetes 42%
Atrial fibrillation 38%
Heart failure 36%
Chronic kidney disease 33%
COPD 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 119 476 $1,926
Injection, aminophyllin, up to 250 mg J0280 Office 21 21 $40

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $313
$313 — —
Repatha
  • Amgen Inc. $276
$276 103 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $131
$131 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $54
$54 — —
ELIQUIS
  • PFIZER INC. $29
  • E.R. Squibb & Sons, L.L.C. $20
$49 410 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

485 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record